Taken together, our findings, involving in-vitro and in-vivo studies at cell, animal and human levels, suggest MaR1 as a promising new therapy for DKD via targeting LGR6-mediated antioxidant pathway. The gene discussed is LGR6; the disease is diabetic kidney disease.